DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20151443

Effect of montelukast as monotherapy in mild persistent asthma

Bharathi Senthilvelan, Harini Gopalakrishnan, Muthukumar Kunchithapatham

Abstract


Background: Leukotriene Receptor Antagonists (LTRAs) have a role in moderate and severe persistent asthma as a steroid sparing agent.  The role of these agents as monotherapy in mild persistent asthma still needs to be determined. Montelukast is FDA approved for use in children >1 year of age. This study was done to assess the effect of montelukast as monotherapy in children with mild persistent asthma.

Methods: A prospective interventional study was conducted in Department of Pediatrics in Chennai Medical College Hospital and Research centre, Trichy, India from June 2014 to August 2015. A 12 week interventional trial to compare the effect of montelukast with placebo in children with mild persistent asthma and 6 months follow up of cases and controls. The assessment was done by clinical scoring and peak expiratory flow rate (PEFR).

Results: At the end of 12 weeks therapy and at 3 months follow up symptom control was significant in the montelukast group. The difference in clinical assessment scoring and PEFR between the montelukast group and placebo group was statistically significant (p<0.01). However at 6 months follow up symptom control in the montelukast group was not significant and the difference between the two groups was not statistically significant (p>0.05).

Conclusions: Montelukast provides significant symptom control and improvement in PEFR in mild persistent asthma compared to placebo. It is effective as monotherapy in mild persistent asthma in children aged 2-12 years. Symptom control is good during therapy and until three months after discontinuation of drug.

 


Keywords


Montelukast, Clinical scoring, PEFR

Full Text:

PDF

References


Wei-Fong Wu, Jiunn-Ren Wu, Zen-Kong. Montelukast as monotherapy in children with mild persistent asthma. Asian Pac J Allergy Immunol. 2009;27(4):173-80.

Bisgaard H, Zielen S, Garcia-Garcia ML, Polos P. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med. 2005;171(4):315–22.

Straub DA, Moeller A, Minocchieri S. The effect of montelukast on lung function and exhaled nitric oxide in infants with early childhood asthma. Eur Respir J. 2005;25(2):289–94.

Global Initiative for Asthma: GINA report-2015.

National Asthma Education and Prevention Program: Expert Panel Report 3 (EPR 3). Guidelines for the diagnosis and management of asthma, 2007.

Bacharier LB, Boner A, Carlsen KH, et al. Diagnosis and treatment of asthma in childhood: A Practall consensus report. Allergy. 2008;63:5-34.